Issue 7/2024
Daskalov, V., Kermedchieva, R.
SOBAL «Pentagram» – Sofia
Objective: The aim of the present study was to present the efficacy of the PreserFlo MicroShunt (Santen, Osaka, Japan) after surgical treatment in patients with open-angle glaucoma.
Material and Methods: A retrospective analysis of patients with open-angle glaucoma after microinvasive glaucoma surgery (MIBS) with PreserFlo implantation with MMC 0.4 mg/mL administered over 2 min intraoperatively was performed. A total of 43 patients (50 eyes) were included, of which 22 men (%) and 21 women (%). The average age is 65.26 years (32 – 91 years). The implantations were carried out in the period 2020-2023. with a follow-up period of two years. Before surgery, all patients had uncompensated IOP on hypotensive therapy. IOP values <= 18mm/Hg without or with additional drug therapy were accepted as successful surgery and function. The operative interventions of all patients were performed by one surgeon at SOBAL “Pentagram”.
Results: After the performed procedure, we reported the effectiveness of the PreserFlo microimplant in reducing IOP, with 82% of the values being = 18mmHg without or with therapy and surgical treatment success with similar results. Also, a reduction in drug therapy was reported, with 91.3% (42 eyes) not requiring it postoperatively for the follow-up period - 2 years, as well as a low rate of reoperation (15.2% - 7 eyes).
Conclusion: With its unique design, superior efficacy, and minimally invasive implantation, the PreserFlo MicroShunt would be a good choice in the treatment of open-angle glaucoma.
Key words: glaucoma, glaucoma surgery, MIGS, MIBS, PreserFlo
Аddress for correspondation:
Daskalov, V.
SOBAL “Pentagram” - Sofia
g.k. Banishora, Vranya St. 109, 111
1309, Sofia